ANDA 63294, held by Astellas. Ceftizoxime Sodium.
As of Nov 16, 2026, ANDA 63294 (Cefizox), held by Astellas, was first approved by FDA on Mar 31, 1994, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 31, 1994 | Original application | Approved | None posted |
| CefizoxEQ 1GM BASE/VIAL · injectable;injection | Ceftizoxime Sodium | Discontinued |
| CefizoxEQ 2GM BASE/VIAL · injectable;injection | Ceftizoxime Sodium | Discontinued |
| Dec 23, 2002 | Supplement 5Manufacturing | Approved | None posted |
| Dec 7, 2000 | Supplement 4Manufacturing | Approved | None posted |
| Mar 29, 1996 | Supplement 1Manufacturing | Approved | None posted |
| Mar 31, 1994 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters